Ratings Merck KGaA

Equities

Real-time Estimate Tradegate Other stock markets 08:10:18 2024-09-10 EDT			5-day change	1st Jan Change
170.25 ^EUR	+0.21%		-2.16%	+18.11%

09-09	German Shares Cheer Likelihood of September ECB Rate Cut	MT
09-03	Merck Gets EU Approval for Keytruda Cancer Therapy	DJ

The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company returns high margins, thereby supporting business profitability.
Analysts covering this company mostly recommend stock overweighting or purchase.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

The firm trades with high earnings multiples: 24.71 times its 2024 earnings per share.
With an enterprise value anticipated at 3.77 times the sales for the current fiscal year, the company turns out to be overvalued.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
The company's earnings releases usually do not meet expectations.

Source: Surperformance

Source: Refinitiv

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Valuation	Capi. ($)
MERCK KGAA		81.56B
KYOWA KIRIN CO. LTD.		11.99B
YUHAN CORPORATION		6.74B
SK BIOPHARMACEUTICALS CO., LTD.		6.09B
BETTA PHARMACEUTICALS CO., LTD.		2.17B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.		1.97B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-	1.9B
SUPERNUS PHARMACEUTICALS, INC.	-	1.87B
INDIVIOR PLC		1.33B
Average		12.85B
Weighted average by Cap.